NCT03531762View on ClinicalTrials.gov

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions
Healthy
Interventions
DRUG

Tepotinib

Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

DRUG

Omeprazole

Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03531762 - Effect of a Proton Pump Inhibitor on the PK of Tepotinib | Biotech Hunter | Biotech Hunter